when will eli lilly release retatrutide Retatrutide, Lilly's next obesity drug, fueled dramatic weight loss in clinical trial Eli Lilly to release data

For those who receive their GLP-1 prescriptions from an alternative medical provider, Weight Watchers is also offering the GLP-1 Success Program as a standalone option

Retatrutides ~144-hour half-life and tirzepatides ~120-hour half-life both support a single weekly subcutaneous dose, the schedule used in every registrational trial

Yes, and this is the only legitimate way to access it right now

Headline points: Both compounds independently produce dose-related nausea, vomiting, constipation, and decreased appetite

Weight loss during this phase is typically modest

Sowa has learned which strategies actually help patients access the treatment they need